Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KACM001 autologous lymphocyte injection
- Development stage
- Phase 2
- Lead developer
- Bodihekang
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
KACM001 is an autologous lymphocyte injection developed by Beijing Kangai Ruihao Biotechnology. It is a cell-based immunotherapy currently in Phase I/II clinical development in China. The therapy involves the ex vivo expansion and activation of a patient's own lymphocytes, which are then re-infused to target and eliminate cancer cells. It is primarily being investigated for the treatment of advanced, HER2-negative gastric adenocarcinoma in combination with standard-of-care chemotherapy regimens, such as S-1 plus oxaliplatin or cisplatin, for previously untreated locally advanced unresectable or metastatic disease.
- Other names
- KACM001KACM-001KACM 001autologous lymphocyte injection
Beyond the preview
Go deeper on KACM001 autologous lymphocyte injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KACM001 autologous lymphocyte injection.